Laprophan, a Moroccan pharmaceutical group, has obtained the visa from the Moroccan Financial Market Authority (AMMC) for its introduction to the Casablanca Stock Exchange through a capital increase and share sale. The offering, valued at 2.2 billion dirhams, aims to support the company's growth and expansion plans. Laprophan's listing is set to take place through a capital increase of 1.4 billion dirhams and a share sale of 822 million dirhams.
The company's decision to list on the Casablanca Stock Exchange is part of its strategy to strengthen its financial structure and support its industrial development. The offering will consist of 2.4 million shares, representing 37.64% of the company's capital and voting rights. The price of each share is set at 341 dirhams, and the subscription period is scheduled from November 9 to November 17, 2026.
Laprophan is a leading pharmaceutical group in Morocco, with a history spanning over 75 years. The company was founded in 1949 by Dr. Abderrahim Bennis and has since grown into a multinational integrated pharmaceutical platform. Laprophan operates across the entire value chain of pharmaceuticals, from research and development to commercialization, manufacturing, and distribution.
The company has made significant acquisitions in recent years, including the purchase of Amanys Pharma in 2024, which strengthened its position in the hospital segment, oncology, and antibiotic production. In February 2026, Laprophan acquired 60% of the Swiss group Rivopharm, expanding its international presence and portfolio of products.
Laprophan's acquisition strategy is part of its plan to accelerate its growth and expansion. The company has also signed a contract to acquire Corporate Investment Holding, the parent company of laboratory pharmaceutical company Polymedic. The acquisition is subject to regulatory approvals, including clearance from the Competition Council.
Laprophan has a diversified portfolio of over 1,300 marketing authorizations covering 15 major therapeutic areas. The company's model combines proprietary products, licenses, and international partnerships with leading laboratories. Laprophan operates in over 50 countries worldwide, with subsidiaries in eight countries and a workforce of approximately 1,450 employees.
The company's strategic vision is centered around five key axes, including accelerating international expansion, strengthening its position in Morocco, and pursuing selective external growth. Laprophan aims to enrich its product portfolio, reinforce research and development, and implement digital transformation through the integration of ERP SAP S/4HANA RISE.
Key points
- Laprophan's 2.2 billion dirham offering aims to support the company's growth and expansion plans.
- The company's listing on the Casablanca Stock Exchange is set to take place through a capital increase and share sale.
- Laprophan has made significant acquisitions in recent years, including the purchase of Amanys Pharma and Rivopharm.
